For instance, RET fusions were recognized as oncogenic and drug-sensitive rearrangements in approximately 1-2% of lung adenocarcinoma [16, 27] and various multi-kinase inhibitors were actively investigated to treat non-small cell lung cancer. This evidence concerns the gene RET and non-small cell lung carcinoma.